E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Duchenne muscular dystrophy |
|
E.1.1.1 | Medical condition in easily understood language |
Duchenne muscular dystrophy |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10052655 |
E.1.2 | Term | Duchenne muscular dystrophy gene carrier |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10013801 |
E.1.2 | Term | Duchenne muscular dystrophy |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary safety objective of this study is to investigate the safety and tolerability of ascending doses of SGT-001 administered as a single dose IV in adolescents and children with Duchenne muscular dystrophy (DMD).
The primary efficacy objective of this study is to investigate the efficacy of SGT-001 IV in adolescents and children with DMD, by quantifying expression of microdystrophin in muscle biopsies using western blot (WB). |
|
E.2.2 | Secondary objectives of the trial |
• Quantifying expression of microdystrophin via mass spectrometry and immunofluorescence (IF) in muscle biopsies;
• Measuring skeletal muscle mass and composition utilizing magnetic resonance imaging (MRI);
• Assessing skeletal muscle-related function and strength;
• Assessing cardiac and respiratory function;
• Quantifying change in naturalistic motor function at home as measured by Echo5D® (ambient measurement system device);
• Assessing daily activity as measured by Actimyo® (wearable accelerometer); and
• Assessing changes in quality of life and self-reported outcome measures.
Other objectives include quantifying the expression of serum and muscle biomarkers that is associated with microdystrophin production and/or function. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male aged 4 years to 17 years, inclusive, at randomization;
2. Established clinical diagnosis of DMD and documented dystrophin gene mutation predictive of DMD phenotype:
o For children (aged 4 years to 11 years, inclusive), confirmed absence of dystrophin as determined by muscle biopsy IF
(≤ 10% dystrophin-positive fibers) or equivalent methodology, performed following randomization and prior to SGT-001 administration;
3. Anti-AAV9 total/circulating antibody titer <50,000 mU/mL, and anti-AAV9 neutralizing antibody titer ≤1:5;
4. Stable cardiac and pulmonary function;
5. For adolescents (aged 12 years to 17 years, inclusive) the following 2 criteria must be met:
o Unable to walk 10 meters without assistance, AND
o Score ≤4 on Brooke scale for upper extremity;
6. For children (aged 4 years to 11 years, inclusive) the following 2 criteria must be met:
o Walk and climb stairs with/without aid of railing (Vignos scale score
≤3), AND
o Rise from the floor from supine (Gowers) time ≤7 seconds;
7. A stable dose of at least 0.5 mg/kg/day of oral daily prednisone or equivalent for at least 24 weeks prior to dosing and expected to remain constant throughout the study on a per kg basis, except for protocol-specified dose changes;
8. Use of medications frequently prescribed for subjects with DMD will be allowed provided the subject has been on a stable dose for 12 weeks prior to Screening and the dose remains constant throughout the study except for adjustments for weight;
9. Able to understand and comply with all study procedures and have a parent(s) or legal guardian(s) who is able to understand and comply with the study procedure requirements;
10. Be willing to provide informed assent and have a parent(s) or legal guardian(s) who is willing to provide written informed consent for the subject to participate in the study; and
11. Subjects of reproductive potential should utilize double barrier contraceptive methods during the duration of the study. These may include (but are not limited to) condom plus other highly effective contraceptive method (such as hormonal contraceptive or intrauterine device). |
|
E.4 | Principal exclusion criteria |
1. Any prior or ongoing medical condition, medical history, physical findings, ECG findings, or laboratory abnormality that, in the Investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results;
2. Abnormal liver function (gamma-glutamyl transferase >1.5 x upper limit of normal [ULN] or total bilirubin >ULN);
3. Abnormal renal function (cystatin C >1.2 x ULN);
4. Clinically significant abnormalities of coagulation including international normalized ratio (INR) or activated partial thromboplastin time (aPTT) >1.2 x ULN or platelets <125,000 cell/mm3;
5. Impaired cardiovascular function (shortening fraction <28%, EF <45% on cardiac MRI or ECHO, according to feasibility/age group);
6. Respiratory function predictive of (or requiring) the use of daytime ventilatory support, or
o FVC % predicted <60% (age 4-11 years);
o FVC % predicted <40%, and/or FVC <1 L (age ≥ 12 years);
7. Major surgery within 3 months prior to recruitment or planned orthopedic surgery for any time during this study which would interfere with the ability to perform outcome measures;
8. Significant spinal deformity and/or presence of spinal rods, which would interfere with positioning or imaging of the subject in the MRI scanner, including, but not limited to, severe scoliosis (ie, Cobb angle ≥ 30 degrees);
9. Body mass index for age ≥ 95th percentile;
10. For children (aged 4 years to 11 years, inclusive), loss of 30 degrees of plantar flexion from the normal range of movement at the ankle joint due to contracture;
11. A need, in the Investigator’s opinion, to undergo an invasive procedure (eg, spinal fusion or surgical contracture release) for 2 years after randomization;
12. Exposure to another investigational drug within 3 months prior to Screening or 5 half-lives since last administration, whichever is longer;
13. Exposure to approved or investigational drugs that may affect dystrophin or utrophin expression in the previous 6 months prior to Screening; or
14. Exposure to an approved or investigational gene transfer drug. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary safety endpoints:
Incidence of adverse events from baseline to 12 months;
Incidence of clinical laboratory abnormalities from baseline to 12 months;
Incidence of abnormalities in vital signs and physical examinations from baseline to 12 months; and
Incidence of abnormalities on electrocardiograms (ECGs) from baseline to 12 months.
Characterization of SGT-001 kinetics, immune response, and shedding:
Viral load count from baseline to 12 months;
Immunological responses: B-cell (total/circulating and neutralizing anti-adeno-associated virus AAV serotype 9 [AAV9] antibody titers) and T-cell reactivity (to AAV9 and microdystrophin) from baseline to 12 months;
Vector biodistribution in blood and muscle biopsy from baseline to 12 months; and
AAV9 vector shedding from baseline to 12 months.
Primary efficacy endpoint:
Change from baseline at 12 months (post SGT-001 administration) in microdystrophin protein levels in muscle biopsies (active treatment group), as quantified by WB. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Change from baseline at 12 months (post SGT-001 administration) in microdystrophin protein levels in muscle biopsies (active treatment group), as quantified by mass spectrometry;
Change from baseline at 12 months (post SGT-001 administration) in microdystrophin protein levels in muscle biopsies (active treatment group), as quantified by IF;
Lower and/or upper limb skeletal muscle mass and composition as measured by MRI, including changes from baseline at 12 months in edema, fat composition, cross-sectional area and contractile area in the active treatment group compared to the control group;
Change from baseline at 12 months in the North Star Ambulatory Assessment in the active treatment group compared to the control group (ambulatory children);
Change from baseline at 12 months in time to run 10 meters in the active treatment group compared to the control group (ambulatory children);
Change from baseline at 12 months in time to rise from the floor in the active treatment group compared to the control group (ambulatory children);
Changes from baseline at 12 months in upper limb function in the active treatment group compared to the control group, as measured by the Performance of the Upper Limb functional scale;
Changes from baseline at 12 months in the muscular strength of the upper extremities in the active treatment group compared to the control group, as measured by MyoGrip and MyoPinch myometry;
Changes from baseline at 12 months in daily motor activity in the active treatment group compared to the control group, as measured by a wearable accelerometer (Actimyo) for continuous monitoring;
Changes from baseline at 12 months in naturalistic motor function activity in the active treatment group compared to the control group, as measured by an ambient measurement system (Echo5D) at home;
Changes in respiratory function from baseline at 12 months in the active treatment group compared to the control group, as measured by forced vital capacity (FVC) and forced expiratory volume in 1 second, and sniff nasal inspiratory pressure;
Changes in cardiac function from baseline at 12 months in the active treatment group compared to the control group, as measured by echocardiography (ECHO), including, but not limited to,
ejection fraction (EF), left ventricle end systolic volume, and myocardial peak circumferential strain;
Change from baseline at 12 months on the 6-minute walk test in the active treatment group compared to the control group (ambulatory children);
Changes from baseline at 12 months in exploratory serum and muscle biomarkers in the active treatment group compared to the control group;
Changes from baseline at 12 months in quality of life and self-reported outcome measures in the active treatment group compared to the control group;
Changes from baseline at the intermediate timepoints (Day 45, 3, 6, and 9 months) in microdystrophin in muscle biopsies, as quantified by WB, mass spectrometry, and IF (active treatment group);
For the above endpoints, changes from baseline to intermediate timepoints (Day 45, 3, 6, and 9 months) in the active treatment group compared to the control group;
Changes from baseline at 12 months (and intermediate timepoints) in microdystrophin in muscle biopsies, as quantified by WB, mass spectrometry, and IF (combined active treatment and delayed treatment groups; post SGT-001 treatment); and
For the above endpoints, change from baseline at 12 months (combined active treatment and delayed treatment groups; post SGT-001 treatment). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Open-label untreated control |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 6 |